Genomics Core Facility The goal of the Genomics Core Facility (GCF) is to make genomic analysis products and services widely available to UNC LCCC members at cost-effective prices. Services include: producing low-cost custom microarrays for model organisms;analysis of RNA quality;support of the use of Agilent and Affymetrix gene expression microarrays and aCGH and microRNA microarrays;RNAi screening services;assisting with experimental design and analyzing results;archiving of both Agilent and Affimetrix array data;providing web based pathway analysis software;and providing "walk-up" quantitative PCR analysis. The Core adds value to the Center by making accessible complex and expensive DNA technologies to UNC LCCC members. Well-integrated genomics and bioinformatics groups interact with the microarray user to ensure robust data that is archived appropriately for future use. Highlights of research supported by the Core include: Jen Jen Yeh's profiling studies of gene expression in pancreatic cancers, Charles Perou's profiling of cancer gene expression and the effects of cancer therapeutics, and characterization of gene expression in a wide range of tumor types in support of the Cancer Genome Atlas (TCGA) Project. This year and next will see major changes. The Bioinformatics group, while remaining fully integrated, functionally is evolving into a separate core with multiple functions. The Genomics Core is also expanding to offer new techniques, including mapping of methylation sites, preparation of cDNA libraries from mRNA for mRNA-seq by the NexGen sequencing core;continuing development of an RNAi High-throughput Screening facility for functional genomics studies;and offering Nanostring technology for multiplex quantitative measurement of mRNA without amplification. Lastly, the Agilent and Affimetrix microarray components will be physically consolidated in newly renovated space with the DNA Sequencing, Mammalian Genotyping, and High Throughput (Next-Generation) Sequencing Facility. This will enable the cores to more fully integrate and flexibly service users. In 2009, the core was used by 91 investigators. Peer-review funded members accounted for 87% of total core use. Fifty-five Cancer Center members from eight programs used the core. CCSG funding of $167,411 is requested for 2010, representing 10% of the projected operating costs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392176
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$231,806
Indirect Cost
$72,662
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications